Bradley K. Ackerson

Kaiser Permanente Southern California

Mission Viejo, CA

United States

SCHOLARLY PAPERS

8

DOWNLOADS
Rank 7,979

SSRN RANKINGS

Top 7,979

in Total Papers Downloads

10,721

SSRN CITATIONS
Rank 29,754

SSRN RANKINGS

Top 29,754

in Total Papers Citations

37

CROSSREF CITATIONS

1

Scholarly Papers (8)

1.

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study

Number of pages: 40 Posted: 23 Aug 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 5,580 (2,869)

Abstract:

Loading...

2.

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study

Number of pages: 27 Posted: 02 Sep 2021
Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Moderna, Inc. and Kaiser Permanente Southern California
Downloads 2,155 (13,765)
Citation 7

Abstract:

Loading...

COVID-19, SARS-CoV-2, mRNA-1273, vaccine effectiveness, variants, matched cohort

3.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,110 (14,219)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

4.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 386 (145,079)
Citation 1

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

5.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 381 (147,177)
Citation 5

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

6.

Natural Language Processing for Improved COVID-19 Characterization: Evidence from More than 350,000 Patients in a Large Integrated Health Care System

Number of pages: 19 Posted: 05 Apr 2022
Government of the United States of America - Centers for Disease Control and Prevention (CDC), Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Northern California, Genentech, Inc. - San Francisco, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California and Kaiser Permanente Southern California
Downloads 46 (744,327)

Abstract:

Loading...

Natural language processing, Public health surveillance, SARS-CoV-2, artificial intelligence

7.

Safety of Tetanus, Diphtheria, Acellular Pertussis (Tdap) Vaccination During Pregnancy

Number of pages: 37 Posted: 30 Nov 2021
Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Slaoui Center for Vaccines Research, GSK, GSK, GSK, GSK, GSK, GSK, GSK, GSK, GSK, GSK and Kaiser Permanente Southern California
Downloads 35 (824,633)

Abstract:

Loading...

vaccine safety, Tdap vaccine, maternal immunization, pregnancy, observational study

8.

Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies

Number of pages: 30 Posted: 18 Feb 2022
Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Slaoui Center for Vaccines Research, GSK, GSK, GSK, affiliation not provided to SSRN, affiliation not provided to SSRN, GSK, GSK, GSK, GSK, GSK and Kaiser Permanente Southern California
Downloads 28 (884,056)

Abstract:

Loading...

VACCINE SAFETY, diphtheria-tetanus-acellular pertussis vaccine, congenital anomalies, observational study